Skip to main content
logo
Coeptis Therapeutics Holdings, Inc. (COEP)
NASDAQ: COEP · Real-Time Price · USD
11.31
-0.29 (-2.50%)
Mar 3, 2026, 10:48 AM EST - Market open

COEP Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
0.5---0.080.03
Revenue Growth (YoY)
----143.81%27.68%
Cost of Revenue
0.14----0.96
Gross Profit
0.37---0.08-0.93
Selling, General & Admin
9.975.6213.3534.1814.125.78
Research & Development
1.312.336.670.02-0
Amortization of Goodwill & Intangibles
111---
Operating Expenses
13.5810.0521.4934.214.125.78
Operating Income
-13.22-10.05-21.49-34.2-14.05-6.71
Interest Expense
-0.28-0.4-0.11-0.22-0.19-0.15
Other Non Operating Income (Expenses)
0.21-0.190.330.010.79-2.29
EBT Excluding Unusual Items
-13.29-10.64-21.27-34.41-13.45-9.16
Gain (Loss) on Sale of Assets
--0.04---0-
Other Unusual Items
-0.2-0.2--3.17--
Pretax Income
-13.67-10.88-21.27-37.57-13.45-9.16
Earnings From Continuing Operations
-13.67-10.88-21.27-37.57-13.45-9.16
Minority Interest in Earnings
1.281.06----
Net Income
-12.39-9.81-21.27-37.57-13.45-9.16
Net Income to Common
-12.39-9.81-21.27-37.57-13.45-9.16
Shares Outstanding (Basic)
521110
Shares Outstanding (Diluted)
521110
Shares Change (YoY)
-82.00%49.84%79.70%30.98%79.11%18.53%
EPS (Basic)
-2.40-5.10-16.56-52.57-24.64-30.05
EPS (Diluted)
-2.40-5.10-16.56-52.57-24.64-30.05
Free Cash Flow
-8.35-6.65-7.24-3.88-4.49-3.14
Free Cash Flow Per Share
-1.62-3.46-5.64-5.42-8.23-10.29
Gross Margin
72.96%---100.00%-
Operating Margin
-2638.23%----18727.91%-21823.77%
Profit Margin
-2472.91%----17932.37%-29765.89%
Free Cash Flow Margin
-1667.01%----5985.92%-10195.12%
EBITDA
-12.08-9.05-20.49-33.19-13.6-6.39
D&A For EBITDA
1.141110.450.32
EBIT
-13.22-10.05-21.49-34.2-14.05-6.71
Revenue as Reported
0.5---0.080.03
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q